Table 3.
Demographic variables and physical exam findings for participants with untreated and pharmaceutically treated polycystic ovary syndrome
| Untreated PCOS(N = 115) | COCP (N = 9) | Metformin (N = 6) | P | |
|---|---|---|---|---|
| Age, y | 15 ± 2 | 15 ± 1 | 15 ± 1 | .845 |
| Race, n (%) | .636 | |||
| White | 98 (85) | 9 (100) | 6 (100) | |
| Black | 15 (13) | 0 | 0 | |
| Asian | 2 (2) | 0 | 0 | |
| > 1 Race | 0 | 0 | 0 | |
| Hispanic ethnicity, n (%) | 61 (53) | 6 (67) | 4 (67) | .723 |
| BMI | 33.9 ± 6.4 | 33.7 ± 5.7 | 36.4 ± 5.3 | .621 |
| BMI percentile | 94.1 ± 12.2 | 97.1 ± 1.5 | 98.5 ± 0.6 | .454 |
| Menarche, ya | 12 ± 2 | 12 ± 1 | 11 ± 1 | .291 |
| Duration of mensesa | < .001 | |||
| Normal | 3 (3) | 8 (88) | 1 (17) | |
| 1-2 mo | 33 (30) | 0 | 3 (50) | |
| 3-6 mo | 41 (37) | 0 | 1 (17) | |
| 7-12 mo | 22 (20) | 1 (13) | 1 (17) | |
| > 1 y | 11 (10) | 0 | 0 | |
| Hirsutism a | 6.0 (3.0-11.0) | 3.0 (0.5-5.5) | 1.5 (0.8-5.5) | .007 |
| Acne severity, n (%)a | .245 | |||
| None | 8 (7) | 2 (22) | 1 (17) | |
| Mild | 52 (46) | 4 (45) | 5 (83) | |
| Moderate | 45 (40) | 3 (33) | 0 | |
| Severe | 8 (7) | 0 | 0 | |
| DHEASa | 226.0 ± 135.4 | 209.6 ± 60.1 | 142.0 ± 60.8 | .263 |
| Progesteronea | 0.99 ± 0.86 | 1.16 ± 0.61 | 1.77 ± 3.06 | .240 |
| Estradiola | 50.7 ± 30.8 | 46.4 ± 49.4 | 72.3 ± 55.2 | .153 |
| SHBG a | 19.0 (13.4-27.1) | 102.2 (65.5-123.3) | 12.0 (8.2-16.4) | < .001 |
Data are expressed as median (25th-75th percentile), mean ± SD, or number (% of total).
Abbreviations: BMI, body mass index; COCP, combined oral contraceptive pill; DHEAS, dehydroepiandrosterone sulfate; PCOS, polycystic ovary syndrome; SHBG, sex hormone–binding globulin.
a Missing Microbiome Insulin Sensitivity Study; PCOS values, n = 2.